Hepatitis C Care Cascade in BC
Differences over time, by sex and birth cohort

Núria Chapinal, PhD
Epidemiologist, British Columbia Centre for Disease Control

Outline

• Background
• Objectives
• BC Hepatitis Testers Cohort
• Cascade of care
  • Over time
  • By sex
  • By birth cohort
• Summary
• Questions
Background

• HCV related morbidity and mortality are increasing
• Direct acting antivirals (DAAs) are a game changer in reversing morbidity and mortality increase
• Need to increase screening of undiagnosed individuals and linkage and retention to care of diagnosed individuals for DAA to have population-level impact
• Monitoring HCV population across stages of cascade of care can help assess impact of DAA at population level

Objectives

• To characterize changes in cascade of care in British Columbia from 2000 to 2016
• To identify differences by sex and birth cohort
The BC Hepatitis Testers Cohort (BC-HTC)

HCV Cascade of Care

- Yearly snapshots
- Including all linked HCV cases alive by end of year
- Stages:
  1. Diagnosed (anti-HCV positive)
  2. RNA tested
  3. RNA detected (reactive)
  4. Genotyped
  5. Treatment initiated
  6. Sustained virologic response (SVR) after treatment
HCV Cascade of Care in BC, 2000-2016

Diagnosed RNA tested RNA positive Genotyped Treated SVR

Number of people

Year

2018-02-15

HCV Cascade of Care in BC, 2012

Diagnosed RNA tested RNA positive Genotyped Treated SVR

Number of people

Janjua et al. EBioMedicine 2016
### HCV Cascade of Care in BC, 2016

<table>
<thead>
<tr>
<th>Number of people</th>
<th>Diagnosed</th>
<th>RNA tested</th>
<th>RNA positive</th>
<th>Genotyped</th>
<th>Treated</th>
<th>SVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>10,000</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>20,000</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>30,000</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>40,000</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>50,000</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
<tr>
<td>60,000</td>
<td>82%</td>
<td>74%</td>
<td>87%</td>
<td>46%</td>
<td>87%</td>
<td></td>
</tr>
</tbody>
</table>

### HCV Cascade of Care in BC 2012 vs 2016

<table>
<thead>
<tr>
<th>% of previous stage</th>
<th>2012</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA tested</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>RNA positive</td>
<td>70%</td>
<td>70%</td>
</tr>
<tr>
<td>Genotyped</td>
<td>50%</td>
<td>50%</td>
</tr>
<tr>
<td>Treated</td>
<td>40%</td>
<td>40%</td>
</tr>
<tr>
<td>SVR</td>
<td>30%</td>
<td>30%</td>
</tr>
</tbody>
</table>
Summary

• There has been progress across the cascade of care over time
• Remaining gaps in treatment initiation, especially in younger cohorts
  – Large proportion PWID
• Treatment rate has started to increase with new treatments

Acknowledgements

• BCCDC
  – The BC-HTC Team
  – Public Health Analytics
  – PMR, PHSA
• BCCA
• Ministry of Health
• All data stewards
• Canadian HCV Network

• Funding:
  – BCCDC
  – Canadian Institute of Health Research
Disclaimer

- All inferences, opinions, and conclusions drawn in this presentation are those of the author(s), and do not reflect the opinions or policies of the BC Ministry of Health and Data Steward(s).

Ministry of Health Citations


Thank you!
nuria.chapinal@bccdc.ca

Additional slides
Background

- Monitoring HCV population across stages of cascade of care:
  - Provides a measure of population-level program progress and effectiveness
  - Identifies gaps in access to services and engagement in care and treatment
  - Helps policy makers forecast budgetary impacts of treatments

HCV Cascade of Care in BC, 2016
Birth cohort: <1945
HCV Cascade of Care in BC, 2016
Females

Number of people

- Diagnosed: 84%
- RNA tested: 68%
- RNA positive: 87%
- Genotyped: 44%
- Treated: 89%

<table>
<thead>
<tr>
<th>Diagnosed</th>
<th>RNA tested</th>
<th>RNA positive</th>
<th>Genotyped</th>
<th>Treated</th>
<th>SVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>84%</td>
<td>68%</td>
<td>87%</td>
<td>44%</td>
<td>89%</td>
<td></td>
</tr>
</tbody>
</table>

2018-02-15